285 related articles for article (PubMed ID: 20516195)
1. Modeling T-cell acute lymphoblastic leukemia induced by the SCL and LMO1 oncogenes.
Tremblay M; Tremblay CS; Herblot S; Aplan PD; Hébert J; Perreault C; Hoang T
Genes Dev; 2010 Jun; 24(11):1093-105. PubMed ID: 20516195
[TBL] [Abstract][Full Text] [Related]
2. SCL, LMO1 and Notch1 reprogram thymocytes into self-renewing cells.
Gerby B; Tremblay CS; Tremblay M; Rojas-Sutterlin S; Herblot S; Hébert J; Sauvageau G; Lemieux S; Lécuyer E; Veiga DF; Hoang T
PLoS Genet; 2014 Dec; 10(12):e1004768. PubMed ID: 25522233
[TBL] [Abstract][Full Text] [Related]
3. Monoallelic
Veiga DFT; Tremblay M; Gerby B; Herblot S; Haman A; Gendron P; Lemieux S; Zúñiga-Pflücker JC; Hébert J; Cohen JP; Hoang T
Front Immunol; 2022; 13():867443. PubMed ID: 35401501
[TBL] [Abstract][Full Text] [Related]
4. p16INK4A tumor suppressor gene expression and CD3epsilon deficiency but not pre-TCR deficiency inhibit TAL1-linked T-lineage leukemogenesis.
Fasseu M; Aplan PD; Chopin M; Boissel N; Bories JC; Soulier J; von Boehmer H; Sigaux F; Regnault A
Blood; 2007 Oct; 110(7):2610-9. PubMed ID: 17507663
[TBL] [Abstract][Full Text] [Related]
5. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.
Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA
Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468
[TBL] [Abstract][Full Text] [Related]
6. scid Thymocytes with TCRbeta gene rearrangements are targets for the oncogenic effect of SCL and LMO1 transgenes.
Chervinsky DS; Lam DH; Melman MP; Gross KW; Aplan PD
Cancer Res; 2001 Sep; 61(17):6382-7. PubMed ID: 11522630
[TBL] [Abstract][Full Text] [Related]
7. Disordered T-cell development and T-cell malignancies in SCL LMO1 double-transgenic mice: parallels with E2A-deficient mice.
Chervinsky DS; Zhao XF; Lam DH; Ellsworth M; Gross KW; Aplan PD
Mol Cell Biol; 1999 Jul; 19(7):5025-35. PubMed ID: 10373552
[TBL] [Abstract][Full Text] [Related]
8. High-throughput screening in niche-based assay identifies compounds to target preleukemic stem cells.
Gerby B; Veiga DF; Krosl J; Nourreddine S; Ouellette J; Haman A; Lavoie G; Fares I; Tremblay M; Litalien V; Ottoni E; Kosic M; Geoffrion D; Ryan J; Maddox PS; Chagraoui J; Marinier A; Hébert J; Sauvageau G; Kwok BH; Roux PP; Hoang T
J Clin Invest; 2016 Dec; 126(12):4569-4584. PubMed ID: 27797342
[TBL] [Abstract][Full Text] [Related]
9. NOTCH1 pathway activation is an early hallmark of SCL T leukemogenesis.
Göthert JR; Brake RL; Smeets M; Dührsen U; Begley CG; Izon DJ
Blood; 2007 Nov; 110(10):3753-62. PubMed ID: 17698635
[TBL] [Abstract][Full Text] [Related]
10. OLIG2 (BHLHB1), a bHLH transcription factor, contributes to leukemogenesis in concert with LMO1.
Lin YW; Deveney R; Barbara M; Iscove NN; Nimer SD; Slape C; Aplan PD
Cancer Res; 2005 Aug; 65(16):7151-8. PubMed ID: 16103065
[TBL] [Abstract][Full Text] [Related]
11. Notch1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma.
Lin YW; Nichols RA; Letterio JJ; Aplan PD
Blood; 2006 Mar; 107(6):2540-3. PubMed ID: 16282337
[TBL] [Abstract][Full Text] [Related]
12. Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL.
McCormack MP; Shields BJ; Jackson JT; Nasa C; Shi W; Slater NJ; Tremblay CS; Rabbitts TH; Curtis DJ
Blood; 2013 Sep; 122(12):2093-103. PubMed ID: 23926305
[TBL] [Abstract][Full Text] [Related]
13. SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-T alpha chain expression.
Herblot S; Steff AM; Hugo P; Aplan PD; Hoang T
Nat Immunol; 2000 Aug; 1(2):138-44. PubMed ID: 11248806
[TBL] [Abstract][Full Text] [Related]
14. An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice.
Aplan PD; Jones CA; Chervinsky DS; Zhao X; Ellsworth M; Wu C; McGuire EA; Gross KW
EMBO J; 1997 May; 16(9):2408-19. PubMed ID: 9171354
[TBL] [Abstract][Full Text] [Related]
15. The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia.
Mansour MR; Sanda T; Lawton LN; Li X; Kreslavsky T; Novina CD; Brand M; Gutierrez A; Kelliher MA; Jamieson CH; von Boehmer H; Young RA; Look AT
J Exp Med; 2013 Jul; 210(8):1545-57. PubMed ID: 23857984
[TBL] [Abstract][Full Text] [Related]
16. ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer.
Thoms JA; Birger Y; Foster S; Knezevic K; Kirschenbaum Y; Chandrakanthan V; Jonquieres G; Spensberger D; Wong JW; Oram SH; Kinston SJ; Groner Y; Lock R; MacKenzie KL; Göttgens B; Izraeli S; Pimanda JE
Blood; 2011 Jun; 117(26):7079-89. PubMed ID: 21536859
[TBL] [Abstract][Full Text] [Related]
17. Development and characterization of T cell leukemia cell lines established from SCL/LMO1 double transgenic mice.
Chervinsky DS; Lam DH; Zhao XF; Melman MP; Aplan PD
Leukemia; 2001 Jan; 15(1):141-7. PubMed ID: 11243382
[TBL] [Abstract][Full Text] [Related]
18. A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice.
Draheim KM; Hermance N; Yang Y; Arous E; Calvo J; Kelliher MA
Oncogene; 2011 Mar; 30(10):1252-60. PubMed ID: 21057528
[TBL] [Abstract][Full Text] [Related]
19. SCL/TAL1 in Hematopoiesis and Cellular Reprogramming.
Hoang T; Lambert JA; Martin R
Curr Top Dev Biol; 2016; 118():163-204. PubMed ID: 27137657
[TBL] [Abstract][Full Text] [Related]
20. SCL/TAL1: a multifaceted regulator from blood development to disease.
Porcher C; Chagraoui H; Kristiansen MS
Blood; 2017 Apr; 129(15):2051-2060. PubMed ID: 28179281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
